Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
This study has been completed.
Information provided by (Responsible Party):
First received: June 19, 2009
Last updated: March 31, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 2014|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||September 25, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.